scholarly journals Activities of Faropenem, an Oral β-Lactam, against Recent U.S. Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

2002 ◽  
Vol 46 (2) ◽  
pp. 550-555 ◽  
Author(s):  
Ian A. Critchley ◽  
James A. Karlowsky ◽  
Deborah C. Draghi ◽  
Mark E. Jones ◽  
Clyde Thornsberry ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Respiratory Tract ◽  
Haemophilus Influenzae ◽  
Moraxella Catarrhalis ◽  
Oral Therapy ◽  
Respiratory Tract Infections ◽  
Antimicrobial Agents ◽  
Tract Infections

ABSTRACT The in vitro activities of faropenem and other antimicrobial agents were determined against 4,725 Streptococcus pneumoniae isolates, 2,614 Haemophilus influenzae isolates, and 1,193 Moraxella catarrhalis isolates collected from 273 U.S. laboratories during 1999. Faropenem MICs at which 90% of isolates are inhibited were 0.008, 0.25, and 1 μg/ml for penicillin-susceptible, -intermediate, and -resistant S. pneumoniae strains, respectively; 0.5 and 1 μg/ml for β-lactamase-positive and -negative H. influenzae strains, respectively; and 0.12 and 0.5 μg/ml for β-lactamase-negative and -positive M. catarrhalis strains, respectively. Faropenem holds promise as an oral therapy for community-acquired respiratory tract infections.

Etiological Trends and Antibiotic Susceptibility of Bacterial Strains Causing Respiratory Tract Infections

2020 ◽  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Respiratory Tract ◽  
Haemophilus Influenzae ◽  
Moraxella Catarrhalis ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Bacterial Isolates ◽  
Lower Respiratory Tract Infections ◽  
Streptococcus Pneumonia ◽  
Tract Infections

Background: Lower respiratory tract infections (LTRIs) are emerging as the most common infectious diseases of humans. Antibiotic resistance has increased in all the major pathogens therefore, this project engrossed on defining the current drift of bacterial etiologies of respiratory tract infections among the patients and their antimicrobial susceptibility pattern. Methods: This cross-sectional study with non-probability consecutive sampling was conducted in the microbiology laboratory of Ziauddin Hospital. Bacterial isolates (163) were recuperated from respiratory sputum specimens obtained from patients with lower respiratory tract infections. The pathogens collected for study were Streptococcus pneumonia, Haemophilus influenzae, and Moraxella catarrhalis. Frequencies and percentages were computed for categorical variables like microorganism, gender, age, duration of lower respiratory tract infections, etc. Mean and standard deviation were calculated for quantitative variables like age and infection duration. Furthermore, duration of disease was stratified by post stratification Chi Square with p value ≤ 0.05 was considered significant. Results: Most commonly isolated pathogen is Moraxella catarrhalis 72.39% followed by Haemophilus influenza 14.72% and Streptococcus pneumonia 12.88%. For Streptococcus pneumoniae 47% sensitivity showed to Ampicillin, 52% Penicillin, 61.9% Erythromycin and 57% to Ceftriaxone. For Haemophilus influenzae 100%, sensitivity showed to Ceftriaxone, 100% Amoxicillin and 62.5% Co-trimoxazole. Similarly, for Moraxella catarrhalis 54% sensitivity was showed to Erythromycin, 100% Ceftriaxone and 27% with Levofloxacin. Conclusion: Moraxella catarrhalis, Haemophilus influenzae and Streptococcus pneumoniae were the most common bacterial isolates recovered from LTRIs. We found M. catarrhalis resistant rate was elevated for Levofloxacin, Streptococcus pneumonia for Co-trimoxazole and Haemophilus influenzae to all β-lactams. Keywords: Respiratory Tract Infection; Haemophilus influenzae; Moraxella catarrhalis; Streptococcus pneumonia.

scholarly journals 1582. Delafloxacin Activity Against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014–2018)

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S577-S578
Author(s):  
Dee Shortridge ◽  
Jennifer M Streit ◽  
Michael D Huband ◽  
Robert K Flamm
Keyword(s):  
Streptococcus Pneumoniae ◽  
Haemophilus Influenzae ◽  
Moraxella Catarrhalis ◽  
Active Agent ◽  
The United States ◽  
Multidrug Resistant ◽  
In Vitro Susceptibility ◽  
Amoxicillin Clavulanate ◽  
Tract Infections

Abstract Background Delafloxacin (DLX) is an anionic fluoroquinolone (FQ) antimicrobial that was approved in 2017 by the United States (US) Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections. DLX recently successfully completed a clinical trial for the treatment of community-acquired bacterial pneumonia (CABP). In the present study, in vitro susceptibility (S) results for DLX and comparator agents were determined for CABP pathogens including Streptococcus pneumoniae (SPN), Haemophilus influenzae (HI), H. parainfluenzae (HP) and Moraxella catarrhalis (MC) clinical isolates from US hospitals participating in the SENTRY Program during 2014–2018. Methods A total of 1,975 SPN, 1,128 HI, 684 MC, and 43 HP isolates were collected from community-acquired respiratory tract infections (CARTI) during 2014–2018 from US hospitals. Sites included only 1 isolate/patient/infection episode. Isolate identifications were confirmed at JMI Laboratories. Susceptibility testing was performed according to CLSI broth microdilution methodology, and CLSI (2019) breakpoints were applied where applicable. Other antimicrobials tested included levofloxacin (LEV) and moxifloxacin (MOX; not tested in 2015). Multidrug-resistant (MDR) SPN isolates were categorized as being nonsusceptible (NS) to amoxicillin-clavulanate, erythromycin, and tetracycline; other SPN phenotypes were LEV-NS or penicillin (PEN)-NS. β-Lactamase (BL) presence was determined for HI, HP, and MC. Results The activities of the 3 FQs are shown in the table. The most active agent against SPN was DLX, with the lowest MIC50/90 values of 0.015/0.03 mg/L. DLX activities were similar when tested against the MDR or PEN-NS for SPN phenotypes. LEV-NS isolates had DLX MIC50/90 results of 0.12/0.25 mg/L. DLX was the most active FQ against HI, HP, and MC. BL presence did not affect FQ MIC values for HI or MC; only 2 HP isolates were BL-positive. Conclusion DLX demonstrated potent in vitro antibacterial activity against SPN, HI, HP, and MC. DLX was active against MDR SPN that were NS to the agents commonly used as treatments for CABP. DLX had excellent activity against LEV-NS SPN. These data support the continued study of DLX as a potential treatment for CABP. Disclosures All authors: No reported disclosures.

Sign in / Sign up

Export Citation Format

Share Document